Article
Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 1 Dec 2016
Grebely Jason, Dore Gregory J, Zeuzem Stefan, Aspinall Richard J, Fox Raymond, Han Lingling, McNally John, Osinusi Anu, Brainard Diana M, Subramanian G Mani, Natha Macky, Foster Graham R, Mangia Alessandra, Sulkowski Mark, Feld Jordan J
Abstract excerpt
In this analysis of the ASTRAL trials (non-opioid substitution therapy [OST], n = 984; OST, n = 51) evaluating the once-daily, pan-genotypic regimen of sofosbuvir/velpatasvir for hepatitis C virus infection, OST did not impact completion, adherence, sustained virologic response (SVR12), or safety. SVR12 was 96% (95% confidence interval, 87%, >99%) in those receiving OST.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.